Health Catalyst, Inc. (NASDAQ:HCAT) Insider Kevin Lee Freeman Sells 7,500 Shares

Health Catalyst, Inc. (NASDAQ:HCAT) insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $8.94, for a total value of $67,050.00. Following the transaction, the insider now directly owns 236,950 shares in the company, valued at approximately $2,118,333. The trade was a 3.07 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Health Catalyst Price Performance

Shares of NASDAQ HCAT opened at $7.94 on Wednesday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. Health Catalyst, Inc. has a fifty-two week low of $5.42 and a fifty-two week high of $11.41. The firm has a market capitalization of $483.15 million, a PE ratio of -5.88 and a beta of 1.31. The stock’s 50-day simple moving average is $8.14 and its 200-day simple moving average is $7.35.

Health Catalyst (NASDAQ:HCAT) last issued its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). The business had revenue of $76.40 million for the quarter, compared to analyst estimates of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. Health Catalyst’s revenue was up 3.5% on a year-over-year basis. During the same period last year, the business posted ($0.22) EPS. As a group, equities research analysts forecast that Health Catalyst, Inc. will post -0.33 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in HCAT. Price T Rowe Associates Inc. MD grew its stake in Health Catalyst by 6.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 49,746 shares of the company’s stock worth $375,000 after buying an additional 2,831 shares during the last quarter. SG Americas Securities LLC purchased a new position in Health Catalyst during the 2nd quarter worth approximately $187,000. Nepsis Inc. grew its stake in Health Catalyst by 8.3% during the 2nd quarter. Nepsis Inc. now owns 1,253,080 shares of the company’s stock worth $8,007,000 after buying an additional 95,686 shares during the last quarter. Nisa Investment Advisors LLC grew its stake in Health Catalyst by 461.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock worth $41,000 after buying an additional 5,232 shares during the last quarter. Finally, Perfromance Wealth Partners LLC purchased a new position in shares of Health Catalyst in the 2nd quarter valued at approximately $64,000. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Wall Street Analyst Weigh In

HCAT has been the topic of several research reports. Royal Bank of Canada increased their target price on Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a research note on Thursday, November 7th. Stephens increased their target price on Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 14th. Citigroup increased their target price on Health Catalyst from $9.00 to $10.50 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Evercore ISI increased their price target on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research report on Tuesday, October 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a research report on Friday, October 4th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $11.79.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.